{"entity":{"id":"nct07905183","kind":"trial","name":"A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs","aka":[],"tldr":"A phase 3 trial of Relcobatinib run by Enliven Therapeutics, not yet recruiting.","summary":"A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs is a phase 3 interventional study registered as NCT07905183 by Enliven Therapeutics, with 450 participants planned, started 2026-12-31. Conditions recorded: Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive and Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML. Interventions recorded: ELVN-001 and TKI.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07905183","url":"https://clinicaltrials.gov/study/NCT07905183"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml","aml"],"sections":[],"technologies":[],"targets":[],"drugs":["relcobatinib"],"companies":["enliven-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07905183","phase":"3","setting":"A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs","sponsor":"Enliven Therapeutics","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07905183/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"relcobatinib","kind":"drug","name":"Relcobatinib","route":"/drugs/relcobatinib/"}],"company":[{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/"}]}}